The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review

被引:118
作者
Abufaraj, Mohammad [1 ,2 ]
Dalbagni, Guido [3 ]
Daneshmand, Siamak [4 ]
Horenblas, Simon [5 ]
Kamat, Ashish M. [6 ]
Kanzaki, Ryu [7 ]
Zlotta, Alexandre R. [8 ,9 ]
Shariat, Shahrokh F. [1 ,10 ,11 ,12 ]
机构
[1] Med Univ Vienna, Dept Urol, Vienna, Austria
[2] Univ Jordan, Jordan Univ Hosp, Div Urol, Dept Special Surg, Amman, Jordan
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA
[4] Univ Southern Calif, Inst Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Antoni van Leeuwenhoek Hosp, Div Urol, Dept Surg Oncol, Netherlands Canc Inst, Amsterdam, Netherlands
[6] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[7] Osaka Univ, Dept Gen Thorac Surg, Grad Sch Med, Osaka, Japan
[8] Univ Toronto, Mt Sinai Hosp, Div Urol, Dept Surg, Toronto, ON, Canada
[9] Univ Hlth Network, Toronto, ON, Canada
[10] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[11] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[12] Weill Cornell Med Coll, Dept Urol, New York, NY USA
关键词
Bladder cancer; Metastatic bladder cancer; Lymph node metastasis; Surgery; Metastasectomy; Lymph node dissection; TRANSITIONAL-CELL CARCINOMA; LYMPH-NODE DISSECTION; LONG-TERM-SURVIVAL; UROTHELIAL CARCINOMA; INDUCTION CHEMOTHERAPY; RADICAL CYSTECTOMY; SURGICAL RESECTION; POSTCHEMOTHERAPY SURGERY; PULMONARY METASTASECTOMY; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.eururo.2017.09.030
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: The role of surgery in metastatic bladder cancer (BCa) is unclear. Objective: In this collaborative review article, we reviewed the contemporary literature on the surgical management of metastatic BCa and factors associated with outcomes to support the development of clinical guidelines as well as informed clinical decision-making. Evidence acquisition: A systematic search of English language literature using PubMed-Medline and Scopus from 1999 to 2016 was performed. Evidence synthesis: The beneficial role of consolidation surgery in metastatic BCa is still unproven. In patients with clinically evident lymph node metastasis, data suggest a survival advantage for patients undergoing postchemotherapy radical cystectomy with lymphadenectomy, especially in those with measurable response to chemotherapy (CHT). Intraoperatively identified enlarged pelvic lymph nodes should be removed. Anecdotal reports of resection of pulmonary metastasis as part of multimodal approach suggest possible improved survival in well-selected patients. Cytoreductive radical cystectomy as local treatment has also been explored in patients with metastatic disease, although its benefits remain to be assessed. Conclusions: Consolidative extirpative surgery may be considered in patients with clinically evident pelvic or retroperitoneal lymph nodal metastases but only if they have had a response to CHT. Surgery for limited pulmonary metastases may also be considered in very selected cases. Best candidates are those with resectable disease who demonstrate measurable response to CHT with good performance status. In the absence of data from prospective randomized studies, each patient should be evaluated on an individual basis and decisions made together with the patient and multidisciplinary teams. Patient summary: Surgical resection of metastases is technically feasible and can be safely performed. It may help improve cancer control and eventually survival in very selected patients with limited metastatic burden. In a patient who is motivated to receive chemotherapy and to undergo extirpative surgical intervention, surgery should be discussed with the patient among other consolidation therapies in the setting of multidisciplinary teams. (c) 2017 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:543 / 557
页数:15
相关论文
共 70 条
[1]   Impact of multimodal treatment on survival in patients with metastatic urothelial cancer [J].
Abe, Takashige ;
Shinohara, Nobuo ;
Harabayashi, Toru ;
Sazawa, Ataru ;
Maruyama, Satoru ;
Suzuki, Shin ;
Nonomura, Katsuya .
EUROPEAN UROLOGY, 2007, 52 (04) :1106-1114
[2]   Outcome of Metastasectomy for Urothelial Carcinoma: A Multi-Institutional Retrospective Study in Japan [J].
Abe, Takashige ;
Kitamura, Hiroshi ;
Obara, Wataru ;
Matsumura, Nagahide ;
Tsukamoto, Taiji ;
Fujioka, Tomoaki ;
Hara, Isao ;
Murai, Sachiyo ;
Shinohara, Nobuo ;
Nonomura, Katsuya .
JOURNAL OF UROLOGY, 2014, 191 (04) :932-936
[3]   Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery [J].
Abufaraj, Mohammad ;
Gust, Kilian ;
Moschini, Marco ;
Foerster, Beat ;
Soria, Francesco ;
Mathieu, Romain ;
Shariat, Shahrokh F. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (05) :735-744
[4]   Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy [J].
Apolo, Andrea B. ;
Ostrovnaya, Irina ;
Halabi, Susan ;
Iasonos, Alexia ;
Philips, George K. ;
Rosenberg, Jonathan E. ;
Riches, Jamie ;
Small, Eric J. ;
Milowsky, Matthew I. ;
Bajorin, Dean F. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (07) :499-503
[5]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[6]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[7]   Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? [J].
Bekku, Kensuke ;
Saika, Takashi ;
Kobayashi, Yasuyuki ;
Kioshimoto, Ryo ;
Kanbara, Taiki ;
Nasu, Yasutomo ;
Kumon, Hiromi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) :110-115
[8]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[9]   The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016 [J].
Bex, Axel ;
Ljungberg, Borje ;
van Poppel, Hein ;
Powles, Thomas .
EUROPEAN UROLOGY, 2016, 70 (06) :901-905
[10]   Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only [J].
de Vries, R. R. ;
Nieuwenhuijzen, J. A. ;
Meinhardt, W. ;
Bais, E. M. ;
Horenblas, S. .
EJSO, 2009, 35 (04) :352-355